AstraZeneca, Pfizer, Novartis courting Onyx

After Amgen ($AMGN) pulled the trigger on the bid for Onyx Pharmaceuticals ($ONXX), AstraZeneca ($AZN), Novartis ($NVS) and Pfizer ($PFE) also are reportedly vying for chance to scoop up the company in an acquisition, according to Bloomberg. The news wire reports that the four companies have signed confidentiality agreements and hired advisers, and could make first-round bids this week. Last week, Reuters reported that Pfizer had backed out of the running, citing the news wire's own sources. Story | More on Onyx buyout buzz

Suggested Articles

Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019.

After a rough patch in 2017, the stars seem to be realigning for French CAR-T expert Cellectis, which just closed a $164 million U.S. public offering.

Investment firm Frazier Healthcare Partners has closed its 11th fund—worth $780 million—that will help established companies accelerate their growth.